Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2414

Sort by

Sort Order Select

Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Deborah M. Stephens, John C. Byrd

Blood (2021) 138 (13): 1099–1109.

https://doi.org/10.1182/blood.2020006783

Published: 2021

Journal Articles

Mantle cell lymphoma continues to surprise, and inform!

Michael E. Williams

Blood (2021) 137 (23): 3158–3160.

https://doi.org/10.1182/blood.2020010622

Published: 2021

Journal Articles

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

Blood (2021) 137 (23): 3251–3258.

https://doi.org/10.1182/blood.2020008835

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Under the cover of mantle cell lymphoma

Birgitta Sander

Blood (2020) 136 (12): 1378–1379.

https://doi.org/10.1182/blood.2020006581

Published: 2020

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

Blood (2020) 136 (5): 572–584.

https://doi.org/10.1182/blood.2019002385

Published: 2020

Includes: Supplemental data

Journal Articles

UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells

Samantha A. Swenson, Tyler J. Gilbreath, Heather Vahle, R. Willow Hynes-Smith, Jared H. Graham, Henry C.-H. Law, Catalina Amador, Nicholas T. Woods, Michael R. Green, Shannon M. Buckley

Blood (2020) 136 (3): 299–312.

https://doi.org/10.1182/blood.2019002102

Published: 2020

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Christian Winther Eskelund, Simon Husby, Francesco Favero, Tobias Wirenfeldt Klausen, Francisco German Rodriguez-Gonzalez, Arne Kolstad, Lone Bredo Pedersen, Riikka Katariina Räty, Christian H. Geisler, Mats Jerkeman, Joachim Weischenfeldt, Kirsten Grønbæk

Blood (2020) 135 (22): 2000–2004.

https://doi.org/10.1182/blood.2019003539

Published: 2020

Includes: Supplemental data

Journal Articles

Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen

Chieh Lin Fu, Maria Julia Diacovo

Blood (2020) 135 (10): 778.

https://doi.org/10.1182/blood.2019003479

Published: 2020

Journal Articles

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Mitchell Smith, MD PhD, Opeyemi Jegede, PhD, Samir Parekh, MD, Curtis A. Hanson, MD, Peter Martin, FRCPC, MD MS, Brian G. Till, MD, Michael Crump, MD FRCPC, John P. Leonard, MD, Jonathan W. Friedberg, MD, Brad S. Kahl, MD, Thomas E. Witzig, MD

Blood (2019) 134 (Supplement_1): 751.

https://doi.org/10.1182/blood-2019-129323

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Blood (2019) 134 (Supplement_1): 752.

https://doi.org/10.1182/blood-2019-122191

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia

Blood (2019) 134 (Supplement_1): 847.

https://doi.org/10.1182/blood-2019-130052

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Kentaro Narita, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1630.

https://doi.org/10.1182/blood-2019-126706

Published: 2019

Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 1755.

https://doi.org/10.1182/blood-2019-131498

Published: 2019

Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood (2019) 134 (Supplement_1): 35.

https://doi.org/10.1182/blood-2019-121424

Published: 2019

Journal Articles

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution

Erel Joffe, MDMSc, Anita Kumar, MD, Serena Zheng, Manik Uppal, Kurt S. Bantilan, MPH, Preston Atteberry, David J. Straus, MD, M. Lia Palomba, MD, Ariela Noy, MD, Steven M. Horwitz, MD, Alison J. Moskowitz, MD, Paul A. Hamlin, MD, Matthew J Matasar, MD, Connie Lee Batlevi, MD PhD, Gottfried R. von Keudell, MD PhD, Ahmet Dogan, MDPhD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD

Blood (2019) 134 (Supplement_1): 22.

https://doi.org/10.1182/blood-2019-129563

Published: 2019

Journal Articles

Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes

Nanditha Mallesh, Max Zhao, Franz Elsner, PhD, Hannes Lueling, PhD, Richard Schabath, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD, Peter Krawitz, MD, Wolfgang Kern, MD

Blood (2019) 134 (Supplement_1): 2094.

https://doi.org/10.1182/blood-2019-130483

Published: 2019

NARROW

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Mantle cell lymphoma continues to surprise, and inform!

LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Under the cover of mantle cell lymphoma

The different flavors and splices of MCL

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing

UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells

Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

Niemann-Pick disease with isolated leukemic nonnodal mantle cell lymphoma of the spleen

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

The U1 Spliceosomal RNA: A Novel Non-Coding Hotspot Driver Mutation Independently Associated with Clinical Outcome in Chronic Lymphocytic Leukemia

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution

Knowledge Transfer between Artificial Neural Networks for Different Multicolor Flow Cytometry Protocols Improves Classification Performance for Rare B-Cell Neoplasm Subtypes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only